TY - JOUR
T1 - Recent advances in the understanding and management of kawasaki disease
AU - Rowley, Anne H.
AU - Shulman, Stanford T.
PY - 2010/3
Y1 - 2010/3
N2 - disease (KD) is an acute systemic inflammatory illness of childhood that can result in coronary artery aneurysms, myocardial infarction, and sudden death. Clinical and epidemiologic data point to an unknown infectious agent as the cause. We discovered that an oligoclonal IgA immune response is present in arterial tissue in acute KD. Synthetic versions of prevalent IgA antibodies in the KD arterial wall identify cytoplasmic inclusion bodies in acute KD ciliated bronchial epithelium and other inflamed KD tissues. Light and electron microscopic studies show that the inclusion bodies are consistent with aggregates of viral protein and RNA, and are likely formed by the KD etiologic agent. KD susceptibility is likely to be polygenic. Treatment of gammaglobulin nonresponders usually consists of additional intravenous immunoglobulin, methylprednisolone, and/or infliximab. Additional data regarding KD pathogenesis are urgently needed to provide other targets for therapy for those patients at highest risk of developing coronary artery abnormalities.
AB - disease (KD) is an acute systemic inflammatory illness of childhood that can result in coronary artery aneurysms, myocardial infarction, and sudden death. Clinical and epidemiologic data point to an unknown infectious agent as the cause. We discovered that an oligoclonal IgA immune response is present in arterial tissue in acute KD. Synthetic versions of prevalent IgA antibodies in the KD arterial wall identify cytoplasmic inclusion bodies in acute KD ciliated bronchial epithelium and other inflamed KD tissues. Light and electron microscopic studies show that the inclusion bodies are consistent with aggregates of viral protein and RNA, and are likely formed by the KD etiologic agent. KD susceptibility is likely to be polygenic. Treatment of gammaglobulin nonresponders usually consists of additional intravenous immunoglobulin, methylprednisolone, and/or infliximab. Additional data regarding KD pathogenesis are urgently needed to provide other targets for therapy for those patients at highest risk of developing coronary artery abnormalities.
KW - Coronary artery aneurysm
KW - IgA
KW - Inclusion bodies
KW - Intravenous immunoglobulin
UR - http://www.scopus.com/inward/record.url?scp=77953545816&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953545816&partnerID=8YFLogxK
U2 - 10.1007/s11908-010-0091-6
DO - 10.1007/s11908-010-0091-6
M3 - Review article
C2 - 21308505
AN - SCOPUS:77953545816
SN - 1523-3847
VL - 12
SP - 96
EP - 102
JO - Current Infectious Disease Reports
JF - Current Infectious Disease Reports
IS - 2
ER -